Champions Oncology Inc.

10/16/2026 | Press release | Distributed by Public on 10/16/2026 10:15

Proxy Results (Form 8-K)

Item 5.07. Submission of Matters to a Vote of Security Holders.
On October 14, 2026, Champions Oncology, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). The following matters were submitted to a vote of the stockholders at the Annual Meeting and the voting results were as follows:
1. Election of Directors. The seven director nominees named in the Company's 2026 proxy statement were elected to serve for a one-year term expiring at the 2027 Annual Meeting of Stockholders or until their successors are duly elected and qualified, based upon the following votes:
Director Nominee Votes For Votes Withheld Broker Non-Vote
Robert Brainin 7,904,120 338,790 461,706
Ronnie Morris, M.D. 7,883,105 359,805 461,706
Joel Ackerman 7,549,214 693,696 461,706
David Sidransky, M.D. 7,154,225 1,088,685 461,706
Daniel Mendelson 7,904,471 338,439 461,706
Scott R. Tobin 8,230,372 12,538 461,706
Brian Alexander, M.D. 8,241,264 1,646 461,706
2. Ratification of Appointment of Independent Registered Accounting Firm. The appointment of EisnerAmper LLP to serve as the Company's independent registered public accounting firm for the fiscal year ending April 30, 2027, was ratified as follows:
Votes For Votes Against Abstain
8,702,771 1,845 -
3. Non-binding Advisory Resolution Relating to the Compensation of the Company's Named Executive Officers. The proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as described in the Company's 2026 proxy statement, was approved by the following votes:
Votes For Votes Against Abstain Broker Non-Vote
7,130,832 25,242 1,086,836 461,706
4. Non-binding Advisory Vote on the Frequency of Holding Stockholder Advisory Votes on Executive Compensation. The stockholders of the Company recommended, on a non-binding advisory basis, that the frequency of holding stockholder advisory votes on executive compensation, as described in the Company's 2026 proxy statement, be held every year. The results of this non-binding advisory vote were as follows:
1 Year 2 Years 3 Years Abstain Broker Non-Vote
7,198,608 38,035 1,003,655 2,612 461,706
As a result of the stockholder advisory vote and other factors, the Company intends to hold future non-binding advisory votes on the compensation of our named executive officers on an annual basis.
5. Approval of the 2026 Equity Incentive Plan. The proposal to approve the 2026 Equity Incentive plan, as described in the Company's 2026 proxy statement, was approved by the following votes:
Votes For Votes Against Abstain Broker Non-Vote
6,401,638 754,480 1,086,792 461,706
Champions Oncology Inc. published this content on October 16, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on October 16, 2026 at 16:15 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]